These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 33430604)
1. Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From the TAO Trial. Dillinger JG; Ducrocq G; Elbez Y; Cohen M; Bode C; Pollack C; Petrauskiene B; Henry P; Dorobantu M; French WJ; Wiviott SD; Sabatine MS; Mehta SR; Steg PG Circ Cardiovasc Interv; 2021 Jan; 14(1):e009759. PubMed ID: 33430604 [TBL] [Abstract][Full Text] [Related]
2. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial. Dillinger JG; Ducrocq G; Elbez Y; Cohen M; Bode C; Pollack C; Nicolau JC; Henry P; Kedev S; Wiviott SD; Sabatine MS; Mehta SR; Steg PG Circ Cardiovasc Interv; 2018 Jun; 11(6):e006084. PubMed ID: 29895599 [TBL] [Abstract][Full Text] [Related]
3. Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial. Abtan J; Wiviott SD; Sorbets E; Popovic B; Elbez Y; Mehta SR; Sabatine MS; Bode C; Pollack CV; Cohen M; Moccetti T; Laanmets P; Faxon D; Okreglicki A; Ducrocq G; Steg PG; Arch Cardiovasc Dis; 2021 Mar; 114(3):187-196. PubMed ID: 33518473 [TBL] [Abstract][Full Text] [Related]
4. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. Steg PG; Mehta SR; Pollack CV; Bode C; Cohen M; French WJ; Hoekstra J; Rao SV; Ruzyllo W; Ruiz-Nodar JM; Sabaté M; Widimsky P; Kiss RG; Navarro Estrada JL; Hod H; Kerkar P; Guneri S; Sezer M; Ruda M; Nicolau JC; Cavallini C; Ebrahim I; Petrov I; Kim JH; Jeong MH; Ramos Lopez GA; Laanmets P; Kovar F; Gaudin C; Fanouillere KC; Minini P; Hoffman EB; Moryusef A; Wiviott SD; Sabatine MS; JAMA; 2013 Sep; 310(11):1145-55. PubMed ID: 23995608 [TBL] [Abstract][Full Text] [Related]
5. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials. Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052 [TBL] [Abstract][Full Text] [Related]
6. Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel: The ACCOAST Access Substudy. Porto I; Bolognese L; Dudek D; Goldstein P; Hamm C; Tanguay JF; Ten Berg J; Widimský P; Le Gall N; Zagar AJ; LeNarz LA; Miller D; Montalescot G; JACC Cardiovasc Interv; 2016 May; 9(9):897-907. PubMed ID: 27151605 [TBL] [Abstract][Full Text] [Related]
7. Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry. Bangalore S; Pencina MJ; Kleiman NS; Cohen DJ Circ Cardiovasc Interv; 2014 Jun; 7(3):365-73. PubMed ID: 24736878 [TBL] [Abstract][Full Text] [Related]
8. Timing of Angiography and Outcomes in High-Risk Patients With Non-ST-Segment-Elevation Myocardial Infarction Managed Invasively: Insights From the TAO Trial (Treatment of Acute Coronary Syndrome With Otamixaban). Deharo P; Ducrocq G; Bode C; Cohen M; Cuisset T; Mehta SR; Pollack C; Wiviott SD; Elbez Y; Sabatine MS; Steg PG Circulation; 2017 Nov; 136(20):1895-1907. PubMed ID: 28893843 [TBL] [Abstract][Full Text] [Related]
9. Correlation of Admission Heart Rate With Angiographic and Clinical Outcomes in Patients With Right Coronary Artery ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: HORIZONS-AMI (The Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. Kosmidou I; McAndrew T; Redfors B; Embacher M; Dizon JM; Mehran R; Ben-Yehuda O; Mintz GS; Stone GW J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724652 [TBL] [Abstract][Full Text] [Related]
10. Blood transfusion and ischaemic outcomes according to anemia and bleeding in patients with non-ST-segment elevation acute coronary syndromes: Insights from the TAO randomized clinical trial. Deharo P; Ducrocq G; Bode C; Cohen M; Cuisset T; Mehta SR; Pollack CV; Wiviott SD; Rao SV; Jukema JW; Erglis A; Moccetti T; Elbez Y; Steg PG Int J Cardiol; 2020 Nov; 318():7-13. PubMed ID: 32590084 [TBL] [Abstract][Full Text] [Related]
11. Invasive Versus Medical Management in Patients With Prior Coronary Artery Bypass Surgery With a Non-ST Segment Elevation Acute Coronary Syndrome. Lee MMY; Petrie MC; Rocchiccioli P; Simpson J; Jackson CE; Corcoran DS; Mangion K; Brown A; Cialdella P; Sidik NP; McEntegart MB; Shaukat A; Rae AP; Hood SHM; Peat EE; Findlay IN; Murphy CL; Cormack AJ; Bukov NB; Balachandran KP; Oldroyd KG; Ford I; Wu O; McConnachie A; Barry SJE; Berry C; Circ Cardiovasc Interv; 2019 Aug; 12(8):e007830. PubMed ID: 31362541 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction). Pu J; Ding S; Ge H; Han Y; Guo J; Lin R; Su X; Zhang H; Chen L; He B; Circulation; 2017 Oct; 136(16):1462-1473. PubMed ID: 28844990 [TBL] [Abstract][Full Text] [Related]
13. Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy. Steg PG; Mehta SR; Pollack CV; Bode C; Gaudin C; Fanouillere K; Moryusef A; Wiviott SD; Sabatine MS Am Heart J; 2012 Dec; 164(6):817-24.e13. PubMed ID: 23194481 [TBL] [Abstract][Full Text] [Related]
14. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444 [TBL] [Abstract][Full Text] [Related]
15. Activated clotting time and outcomes during percutaneous coronary intervention for non-ST-segment-elevation myocardial infarction: insights from the FUTURA/OASIS-8 Trial. Ducrocq G; Jolly S; Mehta SR; Rao SV; Patel T; Moreno R; Gao P; Steg PG Circ Cardiovasc Interv; 2015 Apr; 8(4):. PubMed ID: 25873729 [TBL] [Abstract][Full Text] [Related]
16. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Valgimigli M; Frigoli E; Leonardi S; Vranckx P; Rothenbühler M; Tebaldi M; Varbella F; Calabrò P; Garducci S; Rubartelli P; Briguori C; Andó G; Ferrario M; Limbruno U; Garbo R; Sganzerla P; Russo F; Nazzaro M; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Ferrante G; Santarelli A; Sardella G; de Cesare N; Tosi P; van 't Hof A; Omerovic E; Brugaletta S; Windecker S; Heg D; Jüni P; Lancet; 2018 Sep; 392(10150):835-848. PubMed ID: 30153988 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes with positive biomarkers undergoing percutaneous coronary intervention: a report from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Huang X; Chen S; Redfors B; Zhang Y; Souza CF; Mehran R; Bansilal S; Kirtane AJ; Brener SJ; Feite F; Dangas GD; Ben-Yehuda O; Stone GW Coron Artery Dis; 2020 Jan; 31(1):59-65. PubMed ID: 31809479 [TBL] [Abstract][Full Text] [Related]
18. Cerebrovascular events after a primary percutaneous coronary intervention strategy for acute ST-segment-elevation myocardial infarction: analysis from the HORIZONS-AMI Trial. Nikolsky E; Mehran R; Dangas GD; Xu K; Parvataneni R; Witzenbichler B; Guagliumi G; Kornowski R; Généreux P; Brener SJ; Stone GW Circ Cardiovasc Interv; 2015 Apr; 8(4):. PubMed ID: 25858976 [TBL] [Abstract][Full Text] [Related]
19. Clinical Usefulness of PRECISE-DAPT Score for Predicting Bleeding Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Analysis From the SMART-DATE Randomized Trial. Choi KH; Song YB; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Gwon HC; Hahn JY Circ Cardiovasc Interv; 2020 May; 13(5):e008530. PubMed ID: 32354228 [TBL] [Abstract][Full Text] [Related]
20. One-Year Survival After ST-Segment-Elevation Myocardial Infarction in Relation With Prehospital Administration of Dual Antiplatelet Therapy. Danchin N; Puymirat E; Cayla G; Cottin Y; Coste P; Gilard M; Goldstein P; Braun F; Belle L; Montalescot G; Ferrières J; Schiele F; Simon T; Circ Cardiovasc Interv; 2018 Sep; 11(9):e007241. PubMed ID: 30354592 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]